News & Updates

A real-world study during Hong Kong’s Omicron BA.2 wave showed that both molnupiravir and nirmatrelvir/ritonavir effectively lowered the risks of disease progression and all-cause mortality in hospitalized COVID-19 patients not requiring oxygen supplementation on admission. However, mortality risk reduction was larger with nirmatrelvir/ritonavir vs molnupiravir.

In rheumatoid arthritis-related interstitial lung disease (RA-ILD), change over time in the levels of serum proteins, such as matrix metallopeptidase 13 (MMP13) and C-X-C motif ligand chemokine 11 (CXCL11), predict clinical outcomes, a recent study has found. The same is true for baseline clinical factors such as patient age and rheumatoid factor.

Device-guided breathing (DGB), as facilitated by the RESPeRATE device, appears to reduce test anxiety and can boost subsequent test performance among students, according to a recent study.

A fixed-dose combination of albuterol and budesonide, delivered as needed, reduced the risk of severe exacerbations in patients with moderate-to-severe asthma inadequately controlled with corticosteroid maintenance therapy, according to results of the phase III MANDALA trial presented at ATS 2022.

Individuals with a prior COVID-19 infection and who are fully vaccinated against COVID-19 appear to have the greatest immunity to the virus, according to the SIREN* study.

In the treatment of children with poorly controlled asthma, the use of azithromycin helps improve asthma control and reduce exacerbations, according to a study.